Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study

• Nobuya InagakiKyoto University
• Takaaki NishimotoEli Lilly (Japan)
• Yoichi NishiyaBoehringer Ingelheim (Japan)
• Daisuke NittaBoehringer Ingelheim (Japan)